GLP-1s in Menopause: Why Weight Loss Slows and Whether HRT Helps

This article contains affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.

Quick Answer: Menopause can genuinely slow GLP-1 weight loss. The menopausal transition is linked to more visceral fat and lower energy expenditure, so the same dose and habits often produce a smaller deficit than they used to. Hormone therapy (HRT) does not appear to cause weight loss on its own: a review of 28 randomized trials in 28,559 women found no evidence that estrogen, with or without progestogen, changes body weight beyond what menopause causes anyway. But two recent retrospective studies found postmenopausal women on HRT lost more weight on semaglutide or tirzepatide than women not on HRT. That is a promising signal, not proof, since neither study was a randomized trial. If your GLP-1 has stalled, check titration stage, adherence, and food and activity drift before assuming hormones are the reason.

What Changes at Menopause That Affects How a GLP-1 Works

Your GLP-1 has not changed. Your body has. A 2008 longitudinal study in the International Journal of Obesity followed 156 initially premenopausal women for four years, with 24-hour energy expenditure measured by whole-room calorimeter in a subset. Only the women who became postmenopausal showed a significant increase in visceral abdominal fat, alongside a significant drop in estradiol; sleeping energy expenditure fell 1.5 times more in women who became postmenopausal than in those who stayed premenopausal, and their fat oxidation dropped by 32%. The same study recorded that physical activity declined starting about two years before menopause and stayed low (Lovejoy et al., 2008). A 2025 narrative review in Seminars in Reproductive Medicine describes the same pattern from a different angle: declining muscle mass and strength alongside a gain and redistribution of fat toward the abdomen (Juppi, Karppinen, and Laakkonen, 2025). A 2021 review in the Journal of Mid-life Health adds that the exact roles of estrogen, gut hormones, sleep, and the microbiome in driving these changes are still being worked out (Fenton, 2021).

None of this means your GLP-1 stopped working. A GLP-1 medication still reduces appetite and food intake the way it did before menopause. What changed is the other side of the equation: more visceral fat, lower energy expenditure, reduced fat oxidation, and often less activity than before mean the same intake creates a smaller calorie deficit than it used to.

Why Did Calorie Counting Stop Working in Menopause?

Because more than one number in the equation moved at once. In the Lovejoy study, 24-hour and sleeping energy expenditure declined with age, the sleeping decline was steeper in women who became postmenopausal, fat oxidation fell by about a third in that group, and physical activity had already drifted down starting about two years before menopause (Lovejoy et al., 2008). None of those shifts announce themselves day to day. A calorie target that created a real deficit at 45 can quietly land close to maintenance at 52, not because you slipped, but because the baseline you are subtracting from is smaller. The fix is not more willpower, it is recalculating your target against your current weight and current activity level rather than the one you used years ago, and treating strength training as a lever for preserving the muscle that keeps resting expenditure higher.

I'm 52, Postmenopausal, and Losing Much Slower Than My Husband on the Same GLP-1, Is It Hormones, Dose, or Normal?

It is impossible to answer from the comparison alone, and it is worth saying directly: research does not show that women respond worse to GLP-1 medications than men. A 2025 systematic review and meta-analysis in the Journal of Diabetes, covering 14 studies of dulaglutide, exenatide, liraglutide, semaglutide, and retatrutide, found that women lost more weight than men on average, by about 1 kg or 1.7 percentage points of body weight, though the gap varied by drug and was not seen with exenatide (Yang et al., 2025). So the honest starting point is that your husband's result is not a benchmark your body is failing to hit. The more useful comparison is your own baseline: percentage of body weight lost, time at your current dose, adherence, and non-scale markers like waist size and strength. We cover that full comparison, including a clinician-question checklist, in Why Am I Losing Weight Slower Than My Husband on the Same GLP-1?

On a GLP-1 in Menopause and Your Weight Stopped Dropping? What to Investigate First

Work through these in order before concluding the medication, or menopause, is the problem:

• Titration stage. FDA-approved semaglutide and tirzepatide regimens escalate gradually. Zepbound's label starts at 2.5 mg weekly and increases toward maintenance doses of 5 mg, 10 mg, or 15 mg; Wegovy uses a similar step-up schedule. If you are still early in titration, the plateau may simply be "not yet at an effective dose," not a hormone problem.
• Adherence and side effects. Missed doses, delayed refills, or under-eating protein because nausea made food unappealing can all blunt results independent of hormones.
• Food and activity drift. Appetite suppression often makes people stop tracking. Re-track honestly for one week to see whether portions, alcohol, or snacking have crept back in.
• Non-scale progress. Waist measurement, clothing fit, and strength can move even when the scale has not, especially if resistance training has increased muscle while fat drops.
• Menopause-specific factors worth flagging to your clinician. Sleep disruption, vasomotor symptoms, thyroid function, and insulin resistance can all independently affect weight trends and are worth ruling in or out rather than assuming.

If you have genuinely ruled out the first four and are still stuck, that is when a conversation about HRT, a dose change, or a different medication becomes worth having with your prescriber, not before.

What the Evidence Actually Shows About HRT and Weight Loss

The honest answer is that HRT is not a weight-loss treatment, at least not by itself. A Cochrane systematic review of 28 randomized controlled trials in 28,559 women found no evidence that unopposed estrogen, or estrogen combined with a progestogen, changes body weight beyond what women typically experience at menopause anyway (Kongnyuy et al., Cochrane Database of Systematic Reviews, 2000). A 2026 clinical review in Obesity Pillars reinforces the same point in plainer language: "MHT is not indicated as a primary weight loss intervention," and its effect on total body weight is minimal (Younglove, 2026).

That is not the same as "HRT does nothing." The Menopause Society's 2022 position statement is clear that hormone therapy remains the most effective treatment for hot flashes, night sweats, and related sleep disruption. That is its proven lane (The Menopause Society, 2022 Hormone Therapy Position Statement). And the same 2026 review notes that MHT can favorably shift body composition (less visceral fat gain, better preserved lean mass) even in studies where total scale weight barely moved (Younglove, 2026). If you are considering HRT, the evidence-backed reason is symptom relief and body-composition support, not an expectation that the scale will move on its own.

Can HRT Make a GLP-1 Work Better? What the Newer Data Shows

This is where the evidence gets more interesting, and where it is important to be precise about what has and has not been shown. A 2024 retrospective cohort study in Menopause followed postmenopausal women treated with semaglutide for at least three months and found that women on hormone therapy lost more total body weight at every checkpoint: 7% versus 5% at three months, and 16% versus 12% at twelve months. The association held up after adjusting for other factors (Hurtado et al., Menopause, 2024).

A Mayo Clinic team ran the same comparison for tirzepatide, first presented at the Endocrine Society's ENDO 2025 meeting and published in February 2026 in The Lancet Obstetrics, Gynaecology & Women's Health. The study followed 120 postmenopausal women treated with tirzepatide for at least 12 months, with 40 hormone therapy users propensity-matched to 80 non-users. Women on both tirzepatide and hormone therapy lost 19.2% of total body weight at last follow-up versus 14.0% for tirzepatide alone, a 5.2 percentage-point difference (p=0.0023), and a higher proportion of the hormone-therapy group reached at least 20%, 25%, and 30% total weight loss (Castaneda et al., The Lancet Obstetrics, Gynaecology & Women's Health, 2026; plain-language summary at Mayo Clinic News Network).

Both studies point the same direction, and both come with the same limits: they are retrospective, observational, and cannot rule out that women who chose HRT differ in other ways (health status, engagement with care, access) from women who did not. Neither study was a randomized trial, so neither can prove HRT causes better GLP-1 response. The honest framing is "a real, repeated signal worth discussing with your clinician," not "start HRT to boost your GLP-1 results."

Does Estrogen Change Body Composition? What About Progesterone Specifically?

Estrogen decline tracks the body-composition changes described earlier: in the Lovejoy cohort, only the women who became postmenopausal, the group whose estradiol fell significantly, showed a significant visceral fat increase (Lovejoy et al., 2008; Juppi et al., 2025). That is the mechanism side of "does estrogen affect GLP-1 results," a changed metabolic backdrop, not a change to how the medication itself works.

Progesterone is a genuinely open question here. The Hurtado and Castaneda studies above measured "hormone therapy" as a category, most participants on combined estrogen-progestogen or estrogen-only regimens, without isolating progesterone's independent contribution to the weight-loss response. We could not find a study that separates progesterone's effect from estrogen's in this specific interaction. That is an honest gap in the evidence, not a settled "no," and it is not something this page, or anyone, can responsibly claim an answer to yet.

Menopause Made Weight Loss Feel Impossible, Will a GLP-1 Actually Work for Me?

Yes, in the sense that matters most: Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition, and that approval carries no menopause-status carve-out. The medications work by reducing appetite and slowing gastric emptying, mechanisms that do not stop functioning at menopause.

What is fair to expect is that the road may be slower or require more deliberate attention to strength training, protein intake, and calorie recalculation than it would have been at 35, for the metabolic reasons described above. That is a real difference in degree, not a reason to conclude the medication cannot work for you.

Verified GLP-1 and Menopause Programs to Consider

If dose, adherence, and habits check out and you are ready to discuss options with a clinician, here is what RangeYourself currently verifies on both sides of this decision, weight-loss medication and menopause hormone therapy.

GLP-1 prices shown are compounded, cash-pay starting rates and are not FDA-approved finished drug products. Menopause program prices reflect each provider's own published rate for its core hormone-therapy offering. Confirm current pricing on each provider's site before enrolling.

Choose Each Path If…

Choose a GLP-1-first conversation if weight-related metabolic risk (blood sugar, blood pressure, joint strain) is your most pressing concern right now and menopause symptoms are manageable in the meantime.

Choose an HRT-first conversation if hot flashes, night sweats, or sleep disruption are dominating your daily life, since that is where hormone therapy has its strongest, best-established evidence.

Choose to discuss both, staggered, with your clinician if you want to eventually use both but would rather be able to tell which treatment is causing which effect. We break down that full sequencing decision, including a clinician-question checklist, in Should I Start HRT Before Starting a GLP-1?

Do not start, stop, or combine either treatment without your prescriber, and never adjust a dose to try to match someone else's results.

FAQ

Can HRT make a GLP-1 work better?

Possibly. Two retrospective studies found postmenopausal women on hormone therapy lost more weight on semaglutide (16% versus 12% at 12 months) or tirzepatide (19.2% versus 14.0% at last follow-up) than women not on HRT (Hurtado et al., 2024; Castaneda et al., 2026). Both are observational, not randomized, so this is a promising association to discuss with a clinician, not a proven effect.

Does estrogen affect GLP-1 results?

Estrogen decline is linked to more visceral fat and lower resting energy expenditure, which changes the metabolic backdrop a GLP-1 is working against (Lovejoy et al., 2008). Newer retrospective data also link hormone therapy use to a stronger GLP-1 response, though that evidence is not yet randomized.

Does estrogen change body composition?

Yes. Longitudinal data tie the menopausal transition, and its fall in estradiol, to increased visceral abdominal fat, a steeper decline in sleeping energy expenditure, and reduced fat oxidation (Lovejoy et al., 2008; Juppi et al., 2025).

Does progesterone affect weight loss on a GLP-1?

This has not been studied in isolation. The retrospective studies showing a hormone-therapy benefit on GLP-1 weight loss looked at hormone therapy broadly, mostly combined estrogen-progestogen or estrogen-only regimens, without separating out progesterone's independent contribution. That is an open question, not a settled answer in either direction.

Can HRT help me lose weight?

Not reliably on its own. A Cochrane review of 28 randomized trials in 28,559 women found no evidence that estrogen, with or without progestogen, changes body weight beyond what menopause causes anyway (Kongnyuy et al., 2000). HRT's strongest, best-established benefit is symptom relief, hot flashes, night sweats, and sleep, not weight loss.

Why did my weight loss stop after menopause, even on a GLP-1?

Usually because your resting energy expenditure declined and visceral fat redistribution changed the math, not because the medication failed. Work through titration stage, adherence, and food and activity drift first. Those three explain most stalls before hormones need to become the explanation. See the full checklist above.

Medical Disclaimer

RangeYourself provides educational information, not medical advice. Hormone therapy and GLP-1 medications require individualized evaluation and prescribing by licensed clinicians. Never start, stop, combine, or adjust a dose of either treatment without your prescriber.

Sources

• Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR, “Increased visceral fat and decreased energy expenditure during the menopausal transition,” International Journal of Obesity, 2008. pubmed.ncbi.nlm.nih.gov/18332882
• Juppi HK, Karppinen JE, Laakkonen EK, “Menopause and Body Composition: A Complex Field,” Seminars in Reproductive Medicine, 2025. thieme-connect.de
• Fenton A, “Weight, Shape, and Body Composition Changes at Menopause,” Journal of Mid-life Health, 2021. journals.lww.com/jomh
• Kongnyuy EJ, Norman RJ, Flight IHK, Rees MC, “Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution,” Cochrane Database of Systematic Reviews, 2000. cochrane.org
• The Menopause Society, 2022 Hormone Therapy Position Statement, Menopause, 2022. menopause.org
• Younglove C, “Clinical review: Menopause hormone therapy in weight management,” Obesity Pillars, 2026. pmc.ncbi.nlm.nih.gov/PMC13010941
• Hurtado MD, et al., “Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use,” Menopause, 2024. pubmed.ncbi.nlm.nih.gov/38446869
• Castaneda R, Bechenati D, Tama E, et al., “The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study,” The Lancet Obstetrics, Gynaecology & Women's Health, 2026;2(2):E118-E128. thelancet.com
• Yang Y, et al., “Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis,” Journal of Diabetes, 2025. onlinelibrary.wiley.com
• U.S. Food and Drug Administration, Wegovy (semaglutide) Prescribing Information.
• U.S. Food and Drug Administration, Zepbound (tirzepatide) Prescribing Information.
• RangeYourself, “RY Verified Facts, GLP-1 Providers” and “RY Verified Facts, Menopause/HRT Providers,” auto-refreshed.

Insurance coverage for GLP-1 medications and menopause hormone therapy varies widely by plan, provider, and medication type. Coverage is not guaranteed.

RangeYourself may earn a commission if you sign up through links on this page, see how we make money. Rankings and verdicts are based on verified pricing and program structure, never on commissions. Prices change frequently, always confirm current rates on each provider's website before purchasing.

Related Reading

• Why Am I Losing Weight Slower Than My Husband on the Same GLP-1?
• Should I Start HRT Before Starting a GLP-1?
• GLP-1 for Menopausal Weight Gain, What You Need to Know
• Best Online HRT for Perimenopause and Menopause (2026 Guide)